The Australian Pesticides and Veterinary Medicines Authority (APVMA) has published a notice of reconsideration to commence a review of anticoagulant rodenticides, a class of product typically used for the control of rats and mice in and around buildings.
The reconsideration, which will include first generation (warfarin, coumatetralyl and diphacinone) and second generation (brodifacoum, bromadiolone, difenacoum, difethialone and flocoumafen) anticoagulant rodenticides, will allow the APVMA to reassess the potential risks associated with the use of these products and consider whether labels carry adequate instructions to protect the health and safety of people, animals, and the environment.
The first stage of the review will seek public comment on the matters being considered and work plan, with submissions to close on 2 February 2022.
Publication of the notice of reconsideration follows assessment of information received during a public consultation undertaken by the APVMA in 2020, which sought feedback from stakeholders on use patterns for anticoagulant rodenticide products.
Anticoagulant rodenticide products under review may continue to be used in accordance with the APVMA-approved label directions for the duration of the review unless suspended or cancelled.
Information about APVMA-approved products and product labels is available on the APVMA’s PubCRIS database.
More information about the review is available on the APVMA website.
Questions about the review can be directed to Enquiries@apvma.gov.au.